SOTIO, a biotechnology company of the group PPF, has announced the listing of the first patient to the international study of the clinic assessment in the stage I/II of the active cell immunotherapy in the treatment of patients with the lung cancer with help of the preparation CVAC/LuCa. According to SOTIO CEO and PPF shareholder Ladislav Bartoníček, the lung cancer is being diagnosed in nearly two million people every year. According to estimations, this figure will likely grow by 50% by 2030.
Source: www.cianews.cz
